eribulin mesylate + erlotinib
E7389-G000-205
Phase 2 small_molecule completed
Quick answer
eribulin mesylate + erlotinib for Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at Eisai Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eisai Co.,
- Indication
- Non-small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed